Sosei Bolsters GPCR Focus With AbbVie Neurology Deal
Gets $40m Upfront
Executive Summary
The Japanese firm has expanded its partnership with AbbVie into the neurology space, where it hopes to use its unique platform technology to develop up to three drug candidates targeting ‘challenging’ G protein-coupled receptor targets.
You may also be interested in...
Sosei Heptares Adds Lilly To Big Pharma Client List
The Japan-UK group is ending the year on a high, banking $37m upfront from a pact with Eli Lilly that will focus on finding small molecules which modulate G protein-coupled receptor (GPCR) targets.
Sosei Heptares Eyes Asia Build-Out On Internal, External Assets
Japan-UK firm is looking to build on a combination of internal and external assets to pursue a more independent business development path in Japan and beyond, in parallel with ongoing discovery and development collaborations.
Asia Deal Watch: Hansoh, TiumBio Join Forces On Endometriosis Drug In Greater China
Plus deals involving Shionogi/ Grünenthal, CR Biopharma/ImmVira, Elevation Oncology/CSPC, Everest Medicines/TTY Biopharm and Dr. Reddy’s/Slayback